Pharmaceutical & Life Sciences News

PureTech Health’s Vor Biopharma Granted First-in-Class Patent

Nov. 28, 2018, 2:58 PM

PureTech Health’s U.S. affiliate Vor Biopharma has been granted a first-in-class immuno-oncology patent broadly covering its technology platform for the treatment of hematological malignancies.

The patent covers first-in-class novel hematopoietic stem cell technology for targeted immunotherapies in hematologic malignancies.

Vor Biopharma’s technology platform has the goal of potentially expanding the reach of targeted immunotherapies beyond B-cell cancers to a broad range of hematological malignancies, including acute myeloid leukemia.

To read the full article log in. To learn more about a subscription click here.